Humacyte Inc. Company Profile
NASDAQ: HUMAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Humacyte at a glance
Humacyte Inc. (NASDAQ: HUMA) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Durham, NC. Humacyte is led by Dr. Laura E. Niklason M.D., Ph.D. and employs about 184 people. The company's shares have traded publicly since 2020.
At a market capitalization of $123.7 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001818382, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Humacyte do?
Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. Humacyte, Inc. was founded in 2004 and is headquartered in Durham, North Carolina.
Business description based on the company's public filings.
Company information
- Legal name
- Humacyte Inc.
- Ticker
- NASDAQ: HUMA
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Laura E. Niklason M.D., Ph.D.
- Employees
- 184
- Headquarters
- 2525 East North Carolina Highway 54, Durham, NC, United States
- Phone
- 919 313 9633
- Website
- humacyte.com
- IPO year
- 2020
- Market cap
- $123.73M
- SEC CIK
- 0001818382
- Latest annual report
- 10-K · Mar 27, 2026
Companies similar to Humacyte
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CMPXCompass Therapeutics Inc. | 0.6882 | +1.43% | $123.94M | vs HUMA |
| IVVDInvivyd Inc. | 0.4127 | -7.45% | $122.01M | vs HUMA |
| ENGNenGene Therapeutics Inc. | 1.74 | -1.14% | $116.61M | vs HUMA |
| ARMPArmata Pharmaceuticals Inc. | 3.03 | +1.68% | $112.69M | vs HUMA |
| FATEFate Therapeutics Inc. | 0.919 | -9.01% | $111.82M | vs HUMA |
| CRDLCardiol Therapeutics Inc. Class A | 0.8626 | -2.28% | $110.14M | vs HUMA |
| TARAProtara Therapeutics Inc. | 2.28 | -5.00% | $140.38M | vs HUMA |
| STROSutro Biopharma Inc. | 8.60 | -1.38% | $142.77M | vs HUMA |